|
|
Article: Dr. Reddy's Signs Definitive Agreement with 3i for the Strategic Acquisition of betapharm.(Company Profile)
- Article from:
- Business Wire
- Article date:
- February 16, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HYDERABAD, India & FRANKFURT, Germany & AUGSBURG, Germany -- Dr. Reddy's Laboratories (NYSE: RDY):
--betapharm is the fourth-largest generics company in Germany and the fastest growing company in the top 10(1)
--Combination of Dr. Reddy's and betapharm offers an excellent opportunity to build on the unique strengths of each company to emerge as a leading generics player in Europe in the long- term
Dr. Reddy's and 3i, Europe's leading private equity house, jointly announced today that they have entered into a definitive agreement providing for the strategic investment by Dr. Reddy's to acquire 100% of betapharm Group, the fourth-largest generic ...